| gptkbp:instanceOf | gptkb:vaccine 
 | 
                        
                            
                                | gptkbp:alsoKnownAs | gptkb:Johnson_&_Johnson_COVID-19_vaccine gptkb:Ad26.COV2.S
 
 | 
                        
                            
                                | gptkbp:approvalYear | 2021-02-27 (US EUA) 
 | 
                        
                            
                                | gptkbp:category | gptkb:COVID-19_pandemic gptkb:Johnson_&_Johnson_brands
 Vaccines approved by the European Medicines Agency
 
 | 
                        
                            
                                | gptkbp:clinicalTrialPhase | gptkb:ENSEMBLE_trial 
 | 
                        
                            
                                | gptkbp:contains | recombinant, replication-incompetent adenovirus type 26 expressing SARS-CoV-2 spike protein 
 | 
                        
                            
                                | gptkbp:countryOfOrigin | gptkb:United_States 
 | 
                        
                            
                                | gptkbp:developedBy | gptkb:Johnson_&_Johnson gptkb:Janssen_Pharmaceuticals
 
 | 
                        
                            
                                | gptkbp:dosesRequired | 1 
 | 
                        
                            
                                | gptkbp:efficacyAgainstModerateToSevereCOVID19 | 66% 
 | 
                        
                            
                                | gptkbp:efficacyAgainstSevereCOVID19 | 85% 
 | 
                        
                            
                                | gptkbp:emergencyServices | gptkb:European_Union gptkb:United_States
 gptkb:World_Health_Organization
 
 | 
                        
                            
                                | gptkbp:manufacturer | gptkb:Emergent_BioSolutions gptkb:Biological_E._Limited
 gptkb:Janssen_Biologics
 gptkb:Reig_Jofre
 gptkb:Catalent
 gptkb:IDT_Biologika
 
 | 
                        
                            
                                | gptkbp:notRecommendedFor | people with history of severe allergic reaction to vaccine ingredients children under 18 (initially)
 
 | 
                        
                            
                                | gptkbp:rareAdverseEvent | gptkb:Guillain-Barré_syndrome thrombosis with thrombocytopenia syndrome
 
 | 
                        
                            
                                | gptkbp:retired | availability of alternative vaccines risk of rare blood clots
 
 | 
                        
                            
                                | gptkbp:routeOfAdministration | intramuscular injection 
 | 
                        
                            
                                | gptkbp:shelfLife | 2 years (frozen) 3 months (refrigerated)
 
 | 
                        
                            
                                | gptkbp:sideEffect | fever fatigue
 headache
 muscle pain
 pain at injection site
 
 | 
                        
                            
                                | gptkbp:storage | 2–8°C 
 | 
                        
                            
                                | gptkbp:target | gptkb:COVID-19 
 | 
                        
                            
                                | gptkbp:technology | gptkb:viral_vector_vaccine 
 | 
                        
                            
                                | gptkbp:trialCountries | gptkb:Argentina gptkb:Belgium
 gptkb:Brazil
 gptkb:Chile
 gptkb:Colombia
 gptkb:Mexico
 gptkb:Peru
 gptkb:Philippines
 gptkb:South_Africa
 gptkb:United_States
 
 | 
                        
                            
                                | gptkbp:trialParticipants | ~44,000 
 | 
                        
                            
                                | gptkbp:vectorFor | gptkb:adenovirus_serotype_26 
 | 
                        
                            
                                | gptkbp:WHOEmergencyUseListing | 2021-03-12 
 | 
                        
                            
                                | gptkbp:withdrawnOrLimitedUse | United States (2023) 
 | 
                        
                            
                                | gptkbp:bfsParent | gptkb:Johnson_&_Johnson_COVID-19_vaccine 
 | 
                        
                            
                                | gptkbp:bfsLayer | 6 
 | 
                        
                            
                                | https://www.w3.org/2000/01/rdf-schema#label | Janssen COVID-19 vaccine 
 |